BiotechTube
Home/Crossfire Oncology/Rogier Buijsman
RB

Rogier Buijsman

CEO

Crossfire Oncology

Therapeutic Areas

Oncology

Crossfire Oncology Pipeline

DrugIndicationPhase
CFON-026B-cell malignancies (via BTK inhibition)Pre-clinical
BAL0891Oncology (via TTK/PLK1 inhibition)Clinical (Phase not specified)

Leadership Team at Crossfire Oncology

JD
Jos de Man
Head of Chemistry
EE
Erik Ensing
CBO
View full Crossfire Oncology profile